17,261 trials
Chronic Kidney Diseases · Inflammation
Primary: Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels — -4.49; -76.57; -88.12; -91.64 Percent change — p=<0.0001
Glaucoma Open-angle
Primary: IOP (mmHg) Change From Baseline at Week 12 — -8.3; -7.7; -7.5 mmHg
Progressive Metastatic Castrate-Resistant Prostate Cancer
Primary: Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel…
Cannabis Use Disorder
Primary: Marijuana Craving Questionnaire-Short Form Score as a Measure of Behavioral Craving — 45.8; 45.2; 27.7; 22.6 score on a scale
Cancer
Primary: Microvascular Damage/Endothelial Dysfunction — 0 Participants
COVID-19 Disease
Primary: Viral Load Change — -2.50; -1.99 log10 copies/mL — p=0.35
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Anemia · B-Cell Prolymphocytic Leukemia · Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Entospletinib in Combination With Obinutuzumab — 400 mg orally twice-daily
Osteosarcoma
Primary: Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment — 6.5; 5.5 months — p=0.0396
Overweight and Obesity
Primary: Body Weight - Stage A — 101.7; 101.7; 94.5 Kilograms (kg)
Acute Pain · Post Operative Pain · Pain
Primary: Overall Summed Pain Intensity Difference (SPID) — 74.5; 82.4; 96.8; 50.5 score on a scale x hours — p=0.123
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage IV Bladder Urothelial Carcinoma AJCC v7
Primary: Progression-free Survival (PFS) — 11.4 months
B-cell Lymphomas (Phase 1) · Advanced Solid Tumors (Phase 1) · Diffuse Large B-cell Lymphoma (Phase 2)
Primary: Recommended Phase 2 Dose (RP2D) of Tazemetostat as a Single-Agent and in Combination With Prednisolone (Phase 1 Only) — 800 mg BID
Alzheimer Disease · Mild Cognitive Impairment
Primary: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake — 0.00; 0.10; 0.12 SUVR
Renal Cell Carcinoma
Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs